3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Carcinoma, Transitional Cell
1
Interventions
Magnetic Resonance Spectroscopy
13
Temozolomide
11
Specimen Handling
8
X-Rays
7
Biopsy
7
Nuclear Medicine Department, Hospital
6
Radiation
5
Phantoms, Imaging
5
erdafitinib
4
ulixertinib
3
trametinib
3
larotrectinib
3
dabrafenib
3
Radiotherapy
3
tipifarnib
2
selpercatinib
2
palbociclib
2
olaparib
2
ivosidenib
2
ensartinib
2
binimetinib
2
D2C7-(scdsFv)-PE38KDEL
2
vorasidenib
1
veliparib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tazemetostat
1
selinexor
1
sapanisertib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Glioma
×
temsirolimus
×
30 days
×
Clear all
No trials found.